Search

A novel STING agonist, CDGSF, ipsilaterally modified with phosphorothioate and fluorine, was synthesized. The phosphorothioate in CDGSF might be a site for covalent conjugation. Injection of CDGSF generated an immunogenic ("hot") tumor microenvironment to suppress melanoma, more efficiently than dithio CDG. In particular, immunization with SARS-CoV-2 spike protein using CDGSF as an adjuvant elicited an exceptionally high antibody titer and a robust T cell response, overcoming the drawbacks of aluminum hydroxide. These results highlighted the therapeutic potential of CDGSF for cancer immunotherapy and the adjuvant potential of the STING agonist in the SARS-CoV-2 vaccine for the first time.

We developed a host-guest ATP responsive strategy for efficient intracellular delivery of phosphopeptides, employing a pegylated arginine clustered calix[5]arene nanocarrier system that has great capability of recognizing the phosphate moieties on peptides and penetrating the cell membrane.

The solvothermal reaction of H3BO3, Li2B4O7, Na2B4O7·10H2O, 1,2-diaminopropane and pyridine led to a new open framework borate, Li2Na2[B12O19(OH)2] (1). Compound 1 crystallizes in the monoclinic space group C2/c. Its structure contains a large cyclic [B12O22(OH)2]10− cluster, which is connected to six neighboring ones via corner-sharing O atoms to give a 6-connected pcu network via B–O–B bonds. Notably, large shuttle-like pores are observed along the [001] direction as well as 8-ring channels along the [101] direction, leading to an intersecting channel system. UV/vis diffuse reflectance analysis indicates that the compound has a wide transparency range with a short-wavelength absorption edge below 200 nm.